Oct 2021
Conyers advised on the business combination of Roivant Sciences Ltd. with Montes Archimedes Acquisition Corporation (MAAC), a special purchase acquisition company sponsored by Patient Square Capital. Roivant will have an initial market capitalization of around US$7 billion following the combination and a consolidated cash position of approximately US$2.5 billion. In connection with the business combination outstanding shares and warrants of MAAC were exchanged for newly issued Roivant shares and warrants, which began trading on Nasdaq under the ticker symbols “ROIV” and “ROIVW” on 1 October 2021.
Director Neil Henderson and Counsel Robert Alexander of Conyers’ Bermuda office worked alongside Davis Polk on the matter.